Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Eli Lilly and Company
• Treatments: Exenatide; Metformin

Criteria

Inclusion Criteria:

• Subjects with type 2 diabetes

• Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination

• BMI 25-45 kg/m^2

• HbA1c between 7.5 % and 12.0 %, inclusive

Exclusion Criteria:

• Treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening

• Patients previously treated with AC2993

• Patients presently treated with insulin